Veeva (VEEV) Systems and Sarah Cannon Research Institute announced a strategic collaboration to drive speed and efficiency in oncology clinical trials across SCRI’s more than 200 research site locations. SCRI is adopting Veeva Clinical Platform to unify its contract research organization and site management organization on a single platform for seamless data flow across clinical teams and research sites. Veeva Clinical Platform will enable SCRI to simplify and standardize trial processes and information flow, improving how investigators and clinical teams work together and share data. With a connected foundation for clinical research, SCRI will be able to automate key processes and provide a streamlined experience for its sites.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva price target raised to $295 from $280 at Mizuho
- Here’s Why Analysts Are Raising Their Price Targets on Veeva Stock (VEEV)
- Veeva price target raised to $329 from $265 at Citi
- Veeva Systems’ Earnings Call Highlights Strong Growth Amid Uncertainty
- Raymond James sees positive read for Doximity from Veeva trends report